Skip to main content
SpringerLink
Log in

Aflibercept/bevacizumab

Resistant hypertension, worsening of nephropathy and worsening of chronic kidney disease following off-label treatment: 3 case reports

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Hanna RM, et al. Three patients with injection of intravitreal vascular endothelial growth factor inhibitors and subsequent exacerbation of chronic proteinuria and hypertension. Clinical Kidney Journal 12: 92-100, No. 1, Feb 2019. Available from: URL: http://doi.org/10.1093/ckj/sfy060 - USA

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Aflibercept/bevacizumab. Reactions Weekly 1762, 23 (2019). https://doi.org/10.1007/s40278-019-64762-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-019-64762-x

Search

Navigation